Scemblix was granted accelerated approval by the FDA for the treatment of certain patients newly diagnosed with chronic ...

Nomlabofusp program update expected mid-December to include available safety, pharmacokinetic (PK) and frataxin data, as well ...

Novartis has received FDA accelerated approval for Scemblix (asciminib) to treat adults with newly diagnosed Ph+ CML-CP.

In bestowing the pro-housing label on San Francisco, the Department of Housing and Community Development (HCD) said the city ...

Cabozantinib is the active ingredient in two of Exelixis' three approved drugs (Cabometyx and Cometriq) and its strongest US patent covering cabozantinib’s composition of matter expires in 2030.

Yale surgeons have completed Connecticut’s first FDA-approved TAMBE procedure, marking a shift in the treatment of complex ...

With the data under review by the FDA, experts estimate that a substantial population could potentially benefit.

Basel, October 29, 2024 – Novartis announced today that Scemblix ® (asciminib) was granted accelerated approval by the US Food and Drug Administration (FDA) for adult patients with newly diagnosed ...

The FDA granted an accelerated approval to asciminib for newly diagnosed Ph+ chronic myeloid leukemia in the chronic phase.